Analysts Set Health Catalyst, Inc. (NASDAQ:HCAT) Target Price at $4.36

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $4.3636.

HCAT has been the topic of several recent analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $4.00 price objective on shares of Health Catalyst in a report on Tuesday, October 7th. UBS Group restated an “outperform” rating on shares of Health Catalyst in a research note on Tuesday, November 11th. Citigroup decreased their price target on shares of Health Catalyst from $3.50 to $3.25 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Summit Redstone set a $5.00 price objective on shares of Health Catalyst in a report on Friday, August 29th. Finally, William Blair reissued an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $2.61 on Friday. Health Catalyst has a 12-month low of $2.02 and a 12-month high of $8.52. The business’s fifty day simple moving average is $2.83 and its 200-day simple moving average is $3.29. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.46. The company has a market cap of $184.61 million, a PE ratio of -1.64 and a beta of 1.72.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Monday, November 10th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%.The firm had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $75.05 million. Analysts expect that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Julie Larson-Green sold 47,997 shares of Health Catalyst stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $2.67, for a total transaction of $128,151.99. Following the completion of the sale, the director owned 73,573 shares of the company’s stock, valued at $196,439.91. The trade was a 39.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Benjamin Landry sold 27,425 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $2.64, for a total transaction of $72,402.00. Following the completion of the transaction, the general counsel owned 100,000 shares in the company, valued at approximately $264,000. This trade represents a 21.52% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC boosted its holdings in Health Catalyst by 9.9% in the third quarter. First Light Asset Management LLC now owns 13,436,220 shares of the company’s stock valued at $38,293,000 after purchasing an additional 1,206,039 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Health Catalyst by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock valued at $12,243,000 after buying an additional 119,117 shares during the period. Primecap Management Co. CA boosted its stake in shares of Health Catalyst by 3.8% in the first quarter. Primecap Management Co. CA now owns 2,005,116 shares of the company’s stock worth $9,083,000 after buying an additional 72,499 shares during the last quarter. Whetstone Capital Advisors LLC acquired a new stake in Health Catalyst during the first quarter worth about $7,724,000. Finally, Geode Capital Management LLC grew its holdings in Health Catalyst by 11.4% during the second quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock worth $6,269,000 after acquiring an additional 169,580 shares during the period. Hedge funds and other institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.